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A randomised, double 
blind, placebo‑controlled 
trial of megestrol acetate 
or dexamethasone in treating 
symptomatic anorexia in people 
with advanced cancer
David C. Currow1,7*, Paul Glare2, Sandra Louw3, Peter Martin4, Katherine Clark5,6, 
Belinda Fazekas1,7 & Meera R. Agar1
This multi‑site, double blind, parallel arm, fixed dose, randomised placebo controlled phase III study 
compared megestrol acetate 480 mg/day with dexamethasone 4 mg/day for their net effects on 
appetite in people with cancer anorexia. Patients with advanced cancer and anorexia for ≥ 2 weeks 
with a score ≤ 4 (0–10 numeric rating scale (NRS) 0 = no appetite, 10 = best possible appetite) were 
recruited. Participants received megestrol 480 mg or dexamethasone 4 mg or placebo daily for up to 
4 weeks. Primary outcomes were at day 7. Responders were defined as having a ≥ 25% improvement 
in NRS over baseline. There were 190 people randomised (megestrol acetate n = 61; dexamethasone 
n = 67, placebo n = 62). At week 1 (primary endpoint), 79·3% in the megestrol group, 65·5% in the 
dexamethasone group and 58·5% in the placebo group (p = 0.067) were responders. No differences 
in performance status or quality of life were reported. Treatment emergent adverse events were 
frequent (90·4% of participants), and included altered mood and insomnia. Hyperglycemia and deep 
vein thromboses were more frequent when on dexamethasone than the other two arms. There was 
no difference in groups between the three arms, with no benefit seen over placebo with anorexia 
improving in all arms.
Trail registration: The trial was registered on 19/08/2008 with the Australian New Zealand Clinical Trials 
Registry (ACTRN12608000405314).
Anorexia, the loss of appetite, occurs in 30–80% of people with cancer referred to palliative  care1. It contributes 
to impaired quality of life (QoL), increased morbidity and  mortality2. Anorexia is a challenging symptom to 
study, given its subjective nature, its fluctuation and the lack of definition of ‘normal’ appetite for the population 
generally, let alone people with advanced disease. Thus, there are no established thresholds to determine at which 
point a person is considered to have anorexia, nor a critical duration of time before it is considered clinically 
 concerning3,4. Often as part of a pro-inflammatory state, anorexia is associated with raised levels of interleukin-6 
(IL-6) and C-reactive protein (CRP) in people with  cancer5.
Although there has been progress in better defining and understanding cachexia in recent  years6 as part of 
the cancer anorexia cachexia syndrome (CACS), this current study deals specifically with the symptom of loss of 
appetite and its impact on health outcomes including health-related  QoL7–9. Symptomatic treatment of anorexia 
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(which is unlikely to have any effect on cachexia given that cachexia per se does not respond to nutritional sup-
port) remains an unmet clinical need with a number of pharmacological interventions used, but no clear standard 
of care given inconsistent effects on appetite and quality of  life10–12. Importantly, response on one disease state to 
a symptomatic therapy for anorexia does not necessarily translate to benefit for people with  cancer13. Goals of 
therapy for anorexia include maintenance or improvement of appetite while optimising QoL.
Late in life, anorexia can cause significant distress to  patients14. Even with counselling, anorexia is also often 
distressing to families and caregivers, and their perspectives are important when considering  interventions4,15,16. 
In palliating anorexia in people with advanced cancer, an approach which focuses on stimulating appetite, sup-
porting each person’s food preferences, avoiding prescriptive dietary advice and providing education to patients 
and their caregivers, are crucial. This education is to promote a shared understanding about changed goals of 
care and to help to reduce the distress caused by reduced oral intake.
Recommended approaches to appetite stimulation in patients undergoing palliative care for cancer include 
megestrol or  dexamethasone8. Landmark studies have been done in megestrol, but these have not included a 
dexamethasone arm (the most frequently prescribed medication for anorexia in this setting) or a placebo arm, 
and have not had sufficient evidence to make a health economic case for its use (despite the fact that it is off-
patent)17,18. These studies were brought together in three systematic reviews over the last  decade19–21. There is 
one seminal, placebo-controlled randomised trial on dexamethasone for anorexia in which improved appetite 
was seen in the two dexamethasone groups, but with short lived benefits and no improvement in weight or per-
formance status, and no difference in  survival22. Most recently, the European Society for Clinical Nutrition and 
Metabolism (ESPEN) has put forward evidence-based guidelines for nutritional assessment and interventions 
in people with advanced cancer, noting that nutrition has a role in the setting of malnutrition if that is present 
in people with advanced  cancer23.
The study brings together the two most frequently used medications for anorexia in advanced cancer and 
for the first time includes a placebo arm in their comparison and prospective data collection to inform a health 
economic evaluation. There are concerns about the unwanted side effects of both medications. Potentially, these 
side effects may be amplified in advanced cancer and any cost–benefit relationship negated. Other drugs that have 
been trialed but are not in widespread use to treat anorexia in advanced cancer include medroxyprogesterone, 
pentoxifylline, anabolic steroids, cannabinoids, mirtazapine and  olanzapine24–30. Despite evidence supporting 
the use of megestrol for  anorexia20,21, it is not currently prescribed extensively as an appetite stimulant to people 
with advanced cancers, partially due to its cost (despite being off patent, so many jurisdictions do not reimburse 
for the indication of anorexia), and partially because there is a lack of clinical consensus on the optimal dose, 
frequency and treatment duration in this  population24,31.
The aim of this phase III study was to compare megestrol acetate 480 mg/day, dexamethasone 4 mg/day and 
placebo for their net effect on short-term appetite (not cachexia) and QoL in people with advanced cancer. The 
seven day duration was chosen, because if no benefit is seen in that time in this population, it is unlikely to have 
wide clinical uptake.
Participants and methods
Participants. Participants were recruited from 12 centres covering 23 institutions across Australia. Patients 
were included if they were: aged ≥ 18 years; diagnosed with advanced cancer and were known to a palliative 
care team; were mentally competent; able to take oral medications; had a baseline appetite score of ≤ 4 on a 
0–10 numeric rating scale (NRS; where 0 is no appetite and 10 is best possible appetite); and an Eastern Coop-
erative Oncology Group (ECOG) score of 0–3 or Australia-modified Karnofsky performance status (AKPS) 
score of 30–10032,33. Participants were excluded if they: had a history of documented thromboembolic disease 
or an implanted vascular access device without adequate anticoagulation using local protocols; had severe or 
uncontrolled ischemic heart disease, congestive cardiac failure or severe hypertension (systolic blood pres-
sure > 180 mmHg); were taking corticosteroids (excluding inhaled corticosteroids) or progestogens; were tube 
fed; had clinically significant ascites (given theoretical concerns of worsening fluid retention with the active 
interventions); had unmonitored diabetes; had uncontrolled nausea and vomiting; were pregnant or breastfeed-
ing; had an active infection; or had diarrhea within the last 7 days. All participants and, separately, their caregiv-
ers provided written informed consent.
Trial design. This study was conducted in accordance with International Committee on Harmonization—
Good Clinical Practice (ICH GCP)34. The study was approved by the respective human research ethics commit-
tees at each participating site. (Table 1) Participants were randomized 1:1:1 to receive megestrol acetate 480 mg 
(three capsules of 160 mg megestrol), dexamethasone 4 mg (one capsule containing 4 mg dexamethasone and 
two placebo capsules) or placebo (three capsules) daily for up to four weeks. Randomisation schedules were 
developed for each site using random number tables generated at an independent site using block sizes of four. 
The dispensing pharmacist allocated a sequential code according to the supplied schedule. Capsules were pre-
pared in a central manufacturing pharmacy, where tablets were encased in an opaque capsule to have all study 
drugs and placebo appearing identical. All study staff, along with participants were blinded to the treatment 
allocation for the entire duration of the study.
Participants attended a screening visit, a baseline visit, then weekly visits for up to four weeks. A follow-up 
visit was conducted one week after treatment cessation (Fig. 1).
During the four-week treatment period, participants received morning doses of their allocated intervention. 
They underwent weekly assessments of blood glucose levels,  AKPS32,  ECOG33, weight, and Functional Assess-
ment of Anorexia/ Cachexia Therapy (FAACT)35, Memorial Symptom Assessment Scales (MSAS)36, efficacy, 
treatment adherence, adverse events, and concomitant medication review. If participants had not responded to 
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the allocated treatment by the end of each treatment week, they ceased randomised treatment and attended a 
study completion visit.
The primary outcome was the change from baseline in appetite score on a NRS at the end of Week 1. Partici-
pants were considered to be responders if they had a 25% improvement over the baseline score or a one point 
improvement if the baseline score was zero. This is a conservative estimate of the minimum clinically important 
difference in improvement in appetite scores which may be as low as 0.6 points on a 0–10  NRS37. Secondary 
outcomes included weight, performance status (AKPS)32, appetite score using the single appetite distress item 
from the  MSAS36 and the ‘Additional Concerns’ section of the FAACT  questionnaire35; change in general health 
related QoL (Functional Assessment of Cancer Therapy—General; FACT-G)38; and adverse events. An Independ-
ent Data Safety Monitoring Committee (DSMC) monitored adverse events 6 monthly, and ad hoc as required. 
Data were collected prospectively for a health economic analysis and will be reported separately.
Statistical plan. The primary objective was to compare response rates between arms. For there to be a 
clinically meaningful difference between arms (accounting for known harm rates for these medications), it was 
assumed that the background rate would be 20% and there would need to be a difference of 25% between each 
treatment group and the placebo group. Based on previous data, a response rate of 45% in each treatment group 
was therefore assumed. This meant a sample size of 53 participants per group (159 in total) provided 80% power 
with a two-tailed alpha set at 0·05. Analyses were conducted on an intention-to-treat (ITT) basis. Pairwise com-
parisons (megestrol versus placebo; and dexamethasone versus placebo) were conducted using Chi-square tests.
In order to control for multiplicity in the primary endpoint, first the global test of association between treat-
ment group and the primary endpoint was assessed at the 5% significance level. Only if the global test of asso-
ciation was significant were the pairwise treatment comparisons tested at the 5% significance level. Secondary 
outcomes were analysed using the same approach. Changes in weight, AKPS and MSAS appetite scores between 
the placebo group and the megestrol and dexamethasone groups were examined using Mann Whitney U tests. 
Quality of life was analysed using analysis of covariance (ANCOVA) with the baseline result as a covariate, and 
centre and treatment group as predictor variables as was caregiver wellbeing. Adverse events were compared 
using Mann–Whitney U tests.
Table 1.  Full names of ethics committees that approved this study.
Ethics committee Recruitment site Ethics approval date
Mater Health Services Human Ethics Research Com-
mittee Mater Health Services, QLD 03/10/2008
Peter MacCallum Research Centre Peter MacCallum Cancer Centre, VIC 08/01/2009
Flinders Clinical Research Ethics Committee Flinders Medical Centre, SA 10/02/2009
Hollywood Private Hospital Research Ethics committee Hollywood Private Hospital, WA 03/03/2009
Ballarat Health Services SJOGHC Human Research 
Ethics Committee Ballarat Health Services, VIC 01/05/2009
Sydney South West Human Research Ethics Committee 
(RPAH Zone) Braeside Hospital, NSW 09/02/2009
Sydney South West Human Research Ethics Committee 
(RPAH Zone) Camden Hospital, NSW 09/02/2009
Sydney South West Human Research Ethics Committee 
(RPAH Zone) Calvary Mater Newcastle, NSW 09/02/2009
Sydney South West Human Research Ethics Committee 
(RPAH Zone) Liverpool Hospital, NSW 09/02/2009
Flinders Clinical Research Ethics Committee Flinders Private Hospital, NSW 05/05/2009
Flinders Clinical Research Ethics Committee Blackwood Hospital, SA 07/05/2009
Sydney South West Human Research Ethics Committee 
(RPAH Zone) Sacred Heart hospice, NSW 09/02/2009
St Vincent’s Health Human Research Ethics Committee-
D Caritas Christi Hospice, VIC 24/09/2009
St Vincent’s Health Human Research Ethics Committee-
D St Vincent’s Hospital Melbourne, VIC 24/09/2009
Alfred Hospital Ethics Committee The Alfred Hospital, VIC 04/12/2009
Ballarat Health Services and St John of God Health Care 
HREC
St John of God Health Care Ballarat, VIC
25/03/2009
Ballarat Health Services, VIC
St John of God Health Care Ethics Committee
St John of God Hospital Murdoch, WA
08/04/2010
St John of God Health Care Subiaco, WA
Barwon Health Human Research Ethics Committee
Barwon Health Palliative Care Program Geelong , VIC 03/06/2010
Barwon Health Palliative Care Program McKellar 
Centre, VIC 03/06/2010
Alfred Hospital Ethics Committee Caulfield Hospital, VIC 15/12/2010
Hammondcare Health and Hospitals Greenwich Hospital, Hammond Care, NSW 25/09/2012
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In all change-from-baseline analyses, baseline values were used as covariates. No imputation of missing data 
was performed given the weekly review of response for continued participation in the study. Data for participants 
who withdrew early from the study are included up to the point of their discontinuation. Data are presented as 
n (%) or mean (standard deviation (SD)), unless otherwise noted. The study is reported using the CONSORT 
guidance for randomized, controlled  trials39.
Ethics approval and consent to participate. The study was approved by the respective human research 
ethics committees at each participating site.
Results
Participant characteristics. From January 2009 to March 2015, 190 participants typical of a palliative care 
population (Table 2) with anorexia for at least the preceding two weeks were randomised to double-blind treat-
ment (megestrol acetate n = 61; dexamethasone n = 67, placebo n = 62; Fig. 2). All participants had advanced, 
progressive cancer: lung cancer was the most prevalent underlying diagnosis (n = 56, 29·5%) followed by colo-
rectal cancer (n = 25, 13·2%), prostate cancer (n = 23, 12·1%) and other gastrointestinal cancers (n = 20, 10·5%; 
Table 2). Treatment groups were well balanced for demographics and clinical baseline characteristics. The major 
reason for screen failure was the number of people already on a long-term corticosteroid.
Treatment exposure. The mean days of exposure to treatment was greatest in the megestrol group (17.4 
(SD 9.0) days) compared to dexamethasone (15.7 (SD 9.7) days) or placebo (11.7 (SD 8.9) days) predominantly 
reflecting the planned withdrawal from treatment if insufficient response was obtained at the end of each study 
week. (Supplementary Fig. 1) More than half of participants in the placebo group (56.7%) had seven or fewer 
days of treatment, compared to 21.3% in the megestrol arm, and 35.9% in the dexamethasone arm.
Figure 1.  Study diagram for the multi-site, parallel arm, fixed dose, randomised controlled trial of 190 
participants with cancer and anorexia comparing megestrol or dexamethasone with placebo.
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Primary endpoint: NRS appetite response. At week 1 (primary endpoint), 79.3% of participants in the 
megestrol group, 65.5% in the dexamethasone group and 58.5% in the placebo group were responders (Table 3). 
The overall association between treatment group and NRS appetite response was not statistically significant 
(p = 0.067, Wald type 3 Chi-Square for test of treatment association), and thus the primary endpoint of the study 
was not met. The overall pattern of response week by week by group is shown in Supplementary Fig. 2. Therefore, 
pairwise comparisons were not tested. Overall, the odds of a response compared to placebo were 2.68 (95% CI 
1.15–6.23) for participants in the megestrol group, and 1.34 (95% CI 0.62–2.90) for participants in the dexa-
Table 2.  Participant demographics at baseline in a multi-site, parallel arm, fixed dose, randomised controlled 
trial of 190 participants with cancer and anorexia comparing megestrol or dexamethasone with placebo. 
AKPS Australia-modified Karnofsky performance scale, BMI body mass index, ECOG Eastern Co-operative 
Oncology Group, NRS numerical rating scale.
Megestrol acetate 480 mg/day (N = 61) Dexamethasone 4 mg/day (N = 67) Placebo (N = 62)
Age at screening, years, mean (SD) 71.4 (10.9) 71.2 (12.7) 74.7 (10.0)
Gender, n (%)
Male 36 (59.0%) 39 (58.2%) 39 (62.9%)
Female 25 (41.0%) 28 (41.8%) 23 (37.1%)
Weight, kg, mean (SD)
63.1 (14.0) 62.5 (14.6) 62.9 (13.9)
n = 58 n = 64 n = 58
Height, cm, mean (SD)
167.6 (9.9) 167.1 (10.2) 168.2 (10.2)
n = 57 n = 60 n = 57
BMI, kg/m2, mean (SD)
22.36 (3.95) 21.97 (4.00) 22.22 (3.55)
n = 55 n = 60 n = 56
ECOG performance status
0 0 (0.0%) 1 (1.5%) 1 (1.6%)
1 15 (24.6%) 13 (19.4%) 18 (29.0%)
2 29 (47.5%) 29 (43.3%) 31 (50.0%)
3 16 (26.2%) 24 (35.8%) 12 (19.4%)
4 1 (1.6%) 0 (0.0%) 0 (0.0%)
AKPS score, median (min, max) 70 (30, 90) 60 (20, 90) 70 (20, 90)
Baseline NRS for appetite, median 
(min, max) 3 (0, 4) 2 (0, 4) 3 (0, 4)
Figure 2.  CONSORT diagram of a multi-site, parallel arm, fixed dose, randomised controlled trial of 190 
participants with cancer and anorexia comparing megestrol or dexamethasone with placebo.
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methasone group. The high rates of response in all arms in weeks two to four reflects protocol-driven withdrawal 
of participants who failed to achieve an adequate symptomatic response at the end of each treatment period.
Secondary endpoints: Weight. Weight was considered stable if there was a ≤ 1 kg reduction from base-
line. There was no differences in weight stability between groups (p = 0.2417), and therefore pairwise compari-
sons were not conducted.
Change in MSAS appetite scores. Another appetite response was defined as a reduction from baseline 
of one or more distress category on the MSAS. Overall, treatment had a significant effect on MSAS appetite 
response rates at week 1 (68.2% in megestrol group, 38.3% in the dexamethasone group and 48.9% in the placebo 
group, p = 0.0162), however the pairwise comparisons with placebo were not significant (for megestrol/placebo 
(p = 0.0697) nor dexamethasone / placebo (p = 0.3114). There was no difference in the proportion of responders 
on the FAACT anorexia sub-scale.
Quality of life. In participants, there was no difference in QoL from baseline to week 1 in the FACT-G total 
score), nor any of the domain scores. There were no differences in caregivers’ QoL (CQOLC; Table 4).
Other measures. There was no association between treatment group and AKPS maintenance at week 1 
(Table 4).
Adverse events. Almost all participants experienced at least one adverse event (91·4% in megestrol arm, 
89.1% in dexamethasone arm, and 91.7% in the placebo arm). Common Terminology Criteria Grade 3, 4 or 
5 adverse events of special interest occurred in less than 30% of participants (Table  5). In general, the pro-
file of treatment emergent adverse events (TEAE) was similar between all arms. TEAEs of particular inter-
est experienced by most participants were: altered mood (31.1%); insomnia (27.9%); and muscular weakness 
(27.9%) in the megestrol group: insomnia (39.1%); hyperglycaemia (32.8%); and altered mood (31.3%) in the 
dexamethasone group: and muscular weakness (35.0%); oedema (30.0%); altered mood (26.7%); and bone pain 
(26.7%) in the placebo group. There was no statistically significant association between treatment groups and 
the proportion of participants with at least one TEAE of special interest of any grade (p = 0.4346), however there 
was a significant association between hyperglycaemia of any grade and treatment group, with those in the dexa-
methasone group experiencing this event more frequently (32.8%) than either of the other treatment groups 
Table 3.  Proportion of numerical rating scale (NRS) appetite responders by arm at week 1 (the primary 
end-point) and the scores of those who subsequently continued because of their response in week 1. a Note 
participants that failed to achieve a response at the end of each treatment period ceased treatment and 
underwent a follow-up visit.
Megestrol acetate 480 mg Dexamethasone 4 mg Placebo
% N assessable % N assessable % N assessable
Week 1 79.3 58 65.5 58 58.5 53
Week  2a 92.5 40 96.9 32 78.9 19
Week  3a 89.7 29 100.0 28 100.0 12
Week  4a 100.0 22 100.0 20 100.0 10
Follow-up 88.5 52 81.8 44 52.4 42
Table 4.  Secondary endpoints including weight and appetite at week 1 of a multi-site, parallel arm, fixed 
dose, randomised controlled trial of 190 participants with cancer and anorexia comparing megestrol or 
dexamethasone with placebo. Other than hyperglycaemia which was higher in the dexamethasone arm, 
rates of events actively sought were similar between groups. ^MSAS—Memorial Symptom Assessment 
Scale; ^^AKPS—Australia-modified Karnofsky Performance Status scale; *FACT-G: Functional Assessment 
Cachexia Therapy—General; **CQOLC: Caregiver Quality of Life Index—Cancer.
Megestrol acetate 480 mg
p value compared to placebo
Dexamethasone 4 mg
p value  compared to placebo Placebo Overall p value
Weight responders, % 87% 74% 85% 0.2417
MSAS^ responders, % 68.2%p = 0.0697
38.3%
p = 0.3114 48.9% 0.0162
AKPS^^ responders, % 98% 95% 92% 0.3367
Change from baseline in FACT-G* Total 
Score, mean (SD) − 2.1 (3.4) − 4.8 (3.4) − 0.8 (3.4) 0.576
CQOLC** score, mean (SE) 89.6 (7.1) 79.8 (6.5) 81.2 (7.9) 0.520
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(megestrol 16·4% and placebo 11.7%). The differences between dexamethasone and placebo were statistically 
significant (p = 0.0037).
Serious TEAEs occurred in 19 (31.1%), 19 (29.7%) and 20 (33.3%) of participants in the megestrol, dexa-
methasone and placebo arms, respectively. With megestrol, the serious TEAEs experienced were disease progres-
sion (4.9%), deep vein thrombosis (3.3%), general physical health deterioration (3·3%), and sepsis (3·3%). With 
dexamethasone, the most common were deep vein thrombosis (6.3%), lower respiratory tract infection (3.1%), 
urinary tract infection (3·1%), rectal haemorrhage (3.1%), and pathological fracture (3.1%). In the placebo group, 
the most common were disease progression (8·3%), pleural effusion (5%), breathlessness (3·3%), dehydration 
(3·3%), and pneumothorax (3·3%).
There were 10 deaths recorded during the study, and all but two occurred during follow-up. All deaths were 
due to progressive disease although two were considered ‘unexpected’.
Discussion
Overall, there were no statistically significant differences in the treatment effect of megestrol acetate 480 mg or 
dexamethasone 4 mg compared to placebo daily on any of the efficacy endpoints at week 1. The safety profiles of 
megestrol, dexamethasone and placebo were generally similar. As would be expected, participants treated with 
dexamethasone were more likely to experience hyperglycemia.
Other studies of megestrol and dexamethasone for the treatment of cancer-related anorexia have reported 
similar degrees of appetite stimulation in participants treated with dexamethasone 0·75 mg four times daily 
compared to megestrol acetate 800 mg daily, again with non-significant findings, but as with the current study 
the direction of benefit was in favour of  megestrol24, as was one systematic  review40.
The inclusion of a placebo arm in this study is an important advance on previous head-to-head comparisons 
or dose ranging studies. With the placebo arm, the natural history of the variability in NRS appetite scores is 
demonstrated, and no therapy was consistently superior to placebo. Any benefit attributed to one of the study 
medications is likely to be marginal given such a high rate of appetitie improvement in the placebo arm and needs 
to be weighted closely against the directly attributable harms from the intervention medications.
Table 5.  Grade 3, 4 or 5 treatment emergent adverse events of special interest in a multi-site, parallel arm, 
fixed dose, randomised controlled trial of 190 participants with cancer and anorexia comparing megestrol or 
dexamethasone with placebo. Other than hyperglycaemia which was higher in dexamethasone, rates of events 
actively sought were similar between groups.
System organ class/preferred term









Participants with at least one grade 3, 4 or 5 treatment 
emergent adverse event 10 (16.4%) 19 (29.7%) 12 (20.0%)
Gastrointestinal disorders 0 (0.0%) 1 (1.6%) 0 (0.0%)
 Dyspepsia 0 (0.0%) 1 (1.6%) 0 (0.0%)
General disorders and administration site conditions 0 (0.0%) 1 (1.6%) 2 (3.3%)
 Oedema 0 (0.0%) 1 (1.6%) 2 (3.3%)
Metabolism and nutrition disorders 2 (3.3%) 7 (10.9%) 1 (1.7%)
 Hyperglycaemia 1 (1.6%) 7 (10.9%) 1 (1.7%)
 Hyperkalaemia 1 (1.6%) 0 (0.0%) 0 (0.0%)
Musculoskeletal and connective tissue disorders 3 (4.9%) 3 (4.7%) 3 (5.0%)
 Bone pain 1 (1.6%) 1 (1.6%) 1 (1.7%)
 Muscular weakness 1 (1.6%) 2 (3.1%) 2 (3.3%)
 Musculoskeletal disorder 0 (0.0%) 1 (1.6%) 0 (0.0%)
 Osteonecrosis 1 (1.6%) 0 (0.0%) 0 (0.0%)
Psychiatric disorders 3 (4.9%) 2 (3.1%) 3 (5.0%)
 Confusional state 1 (1.6%) 1 (1.6%) 3 (5.0%)
 Insomnia 2 (3.3%) 1 (1.6%) 0 (0.0%)
 Mood altered 1 (1.6%) 0 (0.0%) 0 (0.0%)
Renal and urinary disorders 0 (0.0%) 1 (1.6%) 0 (0.0%)
 Acute kidney injury 0 (0.0%) 1 (1.6%) 0 (0.0%)
Respiratory, thoracic and mediastinal disorders 0 (0.0%) 1 (1.6%) 1 (1.7%)
 Pulmonary embolism 0 (0.0%) 1 (1.6%) 0 (0.0%)
 Pulmonary oedema 0 (0.0%) 0 (0.0%) 1 (1.7%)
Vascular disorders 3 (4.9%) 6 (9.4%) 3 (5.0%)
 Deep vein thrombosis 2 (3.3%) 3 (4.7%) 0 (0.0%)
 Hypertension 1 (1.6%) 3 (4.7%) 2 (3.3%)
 Lymphoedema 0 (0.0%) 0 (0.0%) 1 (1.7%)
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TEAEs remain a problem in participants with late-stage cancer in effectiveness studies. Of particular concern 
are mood alterations and hyperglycaemia, which have the potential to reduce participants’ QoL. It has been 
suggested that fatigue, anorexia-cachexia and depression may share a common pathophysiologic  basis41, and 
therefore it is important to address all symptoms in order to improve QoL. Given the potential for dexamethasone 
to reduce cancer-related fatigue, it provides a possible mechanism for improvements in anorexia in participants 
administered dexamethasone at the significant cost of accelerating catabolic effects on  muscle42. Concerns of 
high rates of thromboembolic disease in people in the megestrol arm were not reflected in the current results, 
with higher rates seen in the dexamethasone arm.
We have previously reported the unblinded rates of dexamethasone stimulating appetite in people with 
advanced life-limiting illnesses, however the data raised concerns about the potential for harms, particularly 
insomnia, psychotropic effects (depression, euphoria) and  hyperglycaemia43.
The study took a long time to accrue despite being a multi-site study that engaged with trial-active clini-
cians. The major reason for problems in recruiting was the widespread use of dexamethasone, often with little 
information in the clinical notes as to why it had been commenced and, importantly, why it was being continued.
The present study is limited by its design, which required participants with insufficient response to cease 
randomised treatment. Therefore, only results at week 1 are reliable for attributing changes in NRS and MSAS 
appetite scores to the arm to which participants were randomised. Like all studies of interventions for subjective 
symptom management, the response seen in the placebo arm includes regression to the mean, natural variability 
in the symptom and a placebo  effect44, potentially obscuring the effect of the pharmacologically active substances 
under evaluation. The only way to overcome this methodological conundrum would be to use complex study 
designs with multiple arms that include “balanced placebos” with the active substances deceptively labeled as 
“placebo” and placebos labeled as “active”45. This study was exploring anorexia only, so measures specific to 
cachexia such as body composition were not undertaken.
The other fundamental challenge was the choice of dose in a study with two active arms. Both medications 
have a dose–response effect, so choice for each when compared to placebo, and especially when compared to each 
other becomes very important in interpreting the results. The exact dose equivalence between dexamethasone 
and megestrol for appetite has not been defined.
There are currently a number of ongoing studies of dexamethasone or megestrol, including a phase III trial 
comparing levocarnitine, celecoxib, carbocisteine and megestrol for increasing lean body mass in people with 
advanced malignancy (EUCTR2010-019831-36-IT). A pilot study of megestrol in combination with formoterol 
in participants with advanced malignancy (EUCTR2008-008857-53-GB) showed promising results for the com-
bination of an anabolic β2-agonist and megestrol to stimulate  appetite46. A phase III evaluation of these findings 
is of great interest to the clinical and scientific community.
This study can inform future studies. In a similar study in the future, an absolute, rather than a relative 
improvement should be used. Given the low rates of thromboembolic events in the megestrol arm, it would be 
reasonable to extend the time until the primary end point to two weeks.
Conclusion
There was little difference between treatment groups in terms of the primary and secondary efficacy endpoints. 
This study does not establish a new standard of care for the symptomatic improvement of anorexia in people 
with advanced cancer.
Data availability
Data are available on request from bona fide researchers.
Code availability
Custom code is also available to bona fide researchers.
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